These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36927054)

  • 1. Hybrid Closed Loop Overcomes the Impact of Missed or Suboptimal Meal Boluses on Glucose Control in Children with Type 1 Diabetes Compared to Sensor-Augmented Pump Therapy.
    Coutant R; Bismuth E; Bonnemaison E; Dalla-Vale F; Morinais P; Perrard M; Trely J; Faure N; Bouhours-Nouet N; Levaillant L; Farret A; Storey C; Donzeau A; Poidvin A; Amsellem-Jager J; Place J; Quemener E; Hamel JF; Breton MD; Tubiana-Rufi N; Renard E
    Diabetes Technol Ther; 2023 Jun; 25(6):395-403. PubMed ID: 36927054
    [No Abstract]   [Full Text] [Related]  

  • 2. Behavioral Patterns and Associations with Glucose Control During 12-Week Randomized Free-Living Clinical Trial of Day and Night Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.
    Emami A; Willinska ME; Thabit H; Leelarathna L; Hartnell S; Dellweg S; Benesch C; Mader JK; Holzer M; Kojzar H; Pieber TR; Arnolds S; Evans ML; Hovorka R
    Diabetes Technol Ther; 2017 Jul; 19(7):433-437. PubMed ID: 28463010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study.
    Lee MH; Vogrin S; Paldus B; Jones HM; Obeyesekere V; Sims C; Wyatt SA; Ward GM; McAuley SA; MacIsaac RJ; Krishnamurthy B; Sundararajan V; Jenkins AJ; O'Neal DN
    Diabetes Technol Ther; 2019 Sep; 21(9):499-506. PubMed ID: 31264889
    [No Abstract]   [Full Text] [Related]  

  • 4. Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes.
    Buckingham BA; Christiansen MP; Forlenza GP; Wadwa RP; Peyser TA; Lee JB; O'Connor J; Dassau E; Huyett LM; Layne JE; Ly TT
    Diabetes Technol Ther; 2018 Sep; 20(9):585-595. PubMed ID: 30070928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm.
    Buckingham BA; Forlenza GP; Pinsker JE; Christiansen MP; Wadwa RP; Schneider J; Peyser TA; Dassau E; Lee JB; O'Connor J; Layne JE; Ly TT
    Diabetes Technol Ther; 2018 Apr; 20(4):257-262. PubMed ID: 29431513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Simplified Semiquantitative Meal Bolus Strategy Combined with Single- and Dual-Hormone Closed-Loop Delivery in Patients with Type 1 Diabetes: A Pilot Study.
    Gingras V; Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Technol Ther; 2016 Aug; 18(8):464-71. PubMed ID: 27191385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
    Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
    Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses.
    Nimri R; Grosman B; Roy A; Nir J; Fisch Shvalb N; Kurtz N; Loewenthal N; Gillon-Keren M; Muller I; Atlas E; Phillip M
    Diabetes Technol Ther; 2021 Apr; 23(4):268-276. PubMed ID: 33185480
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
    Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
    Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial.
    von dem Berge T; Remus K; Biester S; Reschke F; Klusmeier B; Adolph K; Holtdirk A; Thomas A; Kordonouri O; Danne T; Biester T
    Diabetes Obes Metab; 2022 Jul; 24(7):1319-1327. PubMed ID: 35373894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial.
    O'Malley G; Messer LH; Levy CJ; Pinsker JE; Forlenza GP; Isganaitis E; Kudva YC; Ekhlaspour L; Raghinaru D; Lum J; Brown SA;
    Diabetes Technol Ther; 2021 Apr; 23(4):245-252. PubMed ID: 33155824
    [No Abstract]   [Full Text] [Related]  

  • 12. Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial.
    Tauschmann M; Allen JM; Wilinska ME; Thabit H; Stewart Z; Cheng P; Kollman C; Acerini CL; Dunger DB; Hovorka R
    Diabetes Care; 2016 Jul; 39(7):1168-74. PubMed ID: 26740634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial.
    McAuley SA; Lee MH; Paldus B; Vogrin S; de Bock MI; Abraham MB; Bach LA; Burt MG; Cohen ND; Colman PG; Davis EA; Hendrieckx C; Holmes-Walker DJ; Kaye J; Keech AC; Kumareswaran K; MacIsaac RJ; McCallum RW; Sims CM; Speight J; Stranks SN; Sundararajan V; Trawley S; Ward GM; Jenkins AJ; Jones TW; O'Neal DN;
    Diabetes Care; 2020 Dec; 43(12):3024-3033. PubMed ID: 33055139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of hybrid closed-loop insulin delivery activated 24/7 versus evening and night in free-living prepubertal children with type 1 diabetes: A multicentre, randomized clinical trial.
    Renard E; Tubiana-Rufi N; Bonnemaison E; Coutant R; Dalla-Vale F; Bismuth E; Faure N; Bouhours-Nouet N; Farret A; Storey C; Donzeau A; Poidvin A; Amsellem-Jager J; Place J; Breton MD;
    Diabetes Obes Metab; 2022 Mar; 24(3):511-521. PubMed ID: 34816597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
    Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
    Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions.
    Sherr JL; Buckingham BA; Forlenza GP; Galderisi A; Ekhlaspour L; Wadwa RP; Carria L; Hsu L; Berget C; Peyser TA; Lee JB; O'Connor J; Dumais B; Huyett LM; Layne JE; Ly TT
    Diabetes Technol Ther; 2020 Mar; 22(3):174-184. PubMed ID: 31596130
    [No Abstract]   [Full Text] [Related]  

  • 17. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid Close-Loop Systems Versus Predictive Low-Glucose Suspend and Sensor-Augmented Pump Therapy in Patients With Type 1 Diabetes: A Single-Center Cohort Study.
    Lunati ME; Morpurgo PS; Rossi A; Gandolfi A; Cogliati I; Bolla AM; Plebani L; Vallone L; Montefusco L; Pastore I; Cimino V; Argenti S; Volpi G; Zuccotti GV; Fiorina P
    Front Endocrinol (Lausanne); 2022; 13():816599. PubMed ID: 35498423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes.
    Seget S; Rusak E; Polanska J; Jarosz-Chobot P
    Diabetes Technol Ther; 2022 Nov; 24(11):824-831. PubMed ID: 35852811
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
    Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
    Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.